Sugi Predict

Sugi Predict / Compounds / SCHEMBL474618

SCHEMBL474618

SCHEMBL474618

O=C(O)[C@@H]1CCCN1C(=O)Cc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 8/20 0.60
▸ ALDH1A1 P00352 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ ACE2 Q9BYF1 2/20 0.54
▸ MC4R P32245 2/20 0.53
▸ MC3R P41968 2/20 0.53
▸ MC1R Q01726 2/20 0.53
▸ LTA4H P09960 2/20 0.53
▸ CHRM2 P08172 1/20 0.53
▸ CHRM4 P08173 1/20 0.53
▸ CHRM1 P11229 1/20 0.53
▸ CHRM3 P20309 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL474742 1.00 ACE (0.60) ACEALDH1A1SMN1; SMN2L3MBTL1ACE2
SCHEMBL28650436 0.98 ACE (0.58) ACEALDH1A1SMN1; SMN2L3MBTL1ACE2
SCHEMBL12798848 0.95 ACE (0.55) ACEALDH1A1SMN1; SMN2L3MBTL1ACE2
SCHEMBL6786426 0.94 ACE (0.55) ACEALDH1A1SMN1; SMN2CHRM2CHRM4
SCHEMBL3183657 0.94 ACE (0.55) ACEALDH1A1SMN1; SMN2CHRM2CHRM4
SCHEMBL3183667 0.94 ACE (0.55) ACEALDH1A1SMN1; SMN2CHRM2CHRM4
SCHEMBL6039762 0.94 ACE (0.55) ACEALDH1A1SMN1; SMN2CHRM2CHRM4
SCHEMBL5037359 0.91 GYS1 (0.56) ACEALDH1A1SMN1; SMN2ACE2CHRM2
SCHEMBL5037364 0.91 GYS1 (0.56) ACEALDH1A1SMN1; SMN2ACE2CHRM2
SCHEMBL3194380 0.91 ACE (0.54) ACEALDH1A1SMN1; SMN2ACE2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109369494-B Preparation method of N-phenylacetyl-L-proline 中北大学 2021-10-15 — — CN claimed
CN-104788352-A Preparation methods of N-phenylacetyl-L-proline, and N-(1-(phenylacetyl)-L-prolyl)glycine ethyl ester SHANGHAI XUXIN CHEMICAL CO LTD 2015-07-22 — — CN claimed
US-6531612-B2 Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis HOFFMAN-LA ROCHE INC. 2003-03-11 — — US claimed
US-20010008901-A1 Nitrile derivatives that inhibit cathepsin K F. HOFFMANN-LA ROCHE AG (CH) 2001-07-19 — — US claimed
US-4085207-A AND AT LEAST ONE OF N-ACYL-L-TRYPTOPHANS AND N-ACYL-L-PROLINES OTSUKA PHARMACEUTICAL FACTORY, INC. (JA) 1978-04-18 — — US claimed
US-20220356182-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2022-11-10 — — US disclosed
US-20220356182-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2022-11-10 — — US disclosed
CN-109369494-B Preparation method of N-phenylacetyl-L-proline 中北大学 2021-10-15 — — CN disclosed
CN-109369494-B Preparation method of N-phenylacetyl-L-proline 中北大学 2021-10-15 — — CN disclosed
CN-109369494-B Preparation method of N-phenylacetyl-L-proline 中北大学 2021-10-15 — — CN disclosed
US-11053243-B2 Inhibitors of hepatitis C virus replication MERCK SHARP & DOHME CORP. (US) 2021-07-06 — — US disclosed
US-11053243-B2 Inhibitors of hepatitis C virus replication MERCK SHARP & DOHME CORP. (US) 2021-07-06 — — US disclosed
WO-1993021216-A1 BIOLOGICALLY ACTIVE N-ACYLPROLYLDIPEPTIDES HAVING ANTIAMNESTIC, ANTIHYPOXIC AND ANOREXIGENIC EFFECTS RUSSIAN-AMERICAN INSTITUTE FOR NEW DRUG DEVELOPMENT (US) 1993-10-28 — — WO disclosed
US-5219741-A Reacting in the presence of microbiologically produced N-acyl-L-proline acylase DEGUSSA AG (DE) 1993-06-15 — — US disclosed
US-5120652-A Synthesis of proline from acyl derivatives; thermostable DEGUSSA AG (DE) 1992-06-09 — — US disclosed
EP-0416282-A1 Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use Degussa Aktiengesellschaft (DE) 1991-03-13 — — EP disclosed
EP-0019411-B1 1-PHENYL-2-AMINOETHANOL DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS THEREOF IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-12-22 — — EP disclosed
US-4323575-A TOPICAL ANTIINFLAMMATORY AGENTS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1982-04-06 — — US disclosed
EP-0019411-A1 1-Phenyl-2-aminoethanol derivatives, processes for their manufacture and pharmaceutical compositions thereof IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1980-11-26 — — EP disclosed
US-4085207-A AND AT LEAST ONE OF N-ACYL-L-TRYPTOPHANS AND N-ACYL-L-PROLINES OTSUKA PHARMACEUTICAL FACTORY, INC. (JA) 1978-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11053243-B2 Inhibitors of hepatitis C virus replication HAVCR2, HCCS, EIF2AK2 ACE 640/4885ALDH1A1 2400/4885SMN1; SMN2 4833/4885
US-20220356182-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION HAVCR2, HCCS, EIF2AK2 ACE 640/4885ALDH1A1 2400/4885SMN1; SMN2 4833/4885
US-20010008901-A1 Nitrile derivatives that inhibit cathepsin K CTSK, CTSH, CTSS ACE 42/4885ALDH1A1 2193/4885SMN1; SMN2 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.